about
Molecular chaperone properties of serum amyloid P componentHuman serum amyloid P component is a single uncomplexed pentamer in whole serumSerum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosisThe physiological structure of human C-reactive protein and its complex with phosphocholineThe structures of crystalline complexes of human serum amyloid P component with its carbohydrate ligand, the cyclic pyruvate acetal of galactoseTrapping of palindromic ligands within native transthyretin prevents amyloid formationHereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulinProteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesisInteraction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC)Structure of pentameric human serum amyloid P componentThree dimensional structure of human C-reactive proteinInstability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesisTargeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosisDame Sheila Patricia Violet Sherlock. 31 March 1918 - 30 December 2001 Elected FRS 2001Distribution and determinants of circulating complement factor H concentration determined by a high-throughput immunonephelometric assayImaging amyloidosis with radiolabelled SAPHuman serum amyloid P component, a circulating lectin with specificity for the cyclic 4,6-pyruvate acetal of galactose. Interactions with various bacteriaTransgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice.Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo: therapeutic implications for hemolytic-uremic syndrome.Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus.C-reactive protein in childhood dermatomyositis.Serum C-reactive protein measurement in the detection of intercurrent infection in Oriental patients with systemic lupus erythematosusInhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel.Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use.C-reactive protein is essential for innate resistance to pneumococcal infection.C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction.Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease.Low grade inflammation and coronary heart disease: prospective study and updated meta-analysesEffect of alcohol consumption on systemic markers of inflammation.C-reactive protein and atherothrombosis.Targeting C-reactive protein for the treatment of cardiovascular disease.Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction.Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.Hormone binding globulins undergo serpin conformational change in inflammation.The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo.Pathogenesis, diagnosis and treatment of systemic amyloidosis.Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.Role of complement in induction of the allergic response.
P50
Q22254102-53CAB492-2DA0-48A6-A305-C42910144B47Q24290183-11C1B605-B2D4-4EC5-8B1B-76C4DF772DEEQ24562844-BF5C950B-2EEA-4356-B06D-871F4BB8C3FFQ27618638-C1FADBBD-2407-4BF2-A43F-23220526A9FFQ27639384-2967D635-93D1-4AB4-AAD5-E26EC8A50D35Q27665687-C8FA6CBF-BF40-407A-A015-A053ABAA8A9AQ27681150-23A9A726-4F00-4479-AE6F-0CB94236D9ECQ27681502-63690880-87F9-4A48-9141-EA903AE21A24Q27684907-D66B2288-B30F-48BE-B770-A088901D62A3Q27731194-359AB91E-E15C-4E0B-9D97-2A5218D96D1FQ27732605-00531476-A54C-464E-B235-BE06B5A36B1FQ27734827-51b68ba4-42f5-5136-f624-a3da922398eeQ28217930-6CED5871-9373-410B-B6BE-A36B9AF816C6Q28247325-55051BDB-F4EA-47F1-B712-D2BCC2B16F05Q28284799-E2FE41B6-A363-410B-8B16-7F700FAC4602Q28284916-D82E99A8-6114-490E-A757-4A7F0CED41CEQ28362275-2BDD47D9-CDF3-4832-9A40-BADAD9BB5D69Q30475959-5B3410EC-43DA-4746-A198-DE32A552859FQ33370591-F08DA9FC-31C1-451D-A80B-D35212517907Q33552323-11BEFBA6-2DA8-42C5-BDC6-A7EAB26D3EF6Q33553961-99F976BE-D872-400D-998D-0C092BEEFF59Q33555821-DEDBC75B-853F-4F69-B342-FF6C7E5B68A3Q33671132-16573250-E5F0-408C-9D6A-B5E3597082C4Q33796862-C8DDF9B1-B2D2-4805-8799-877F7C210863Q33842663-779D99C9-5BAB-4E85-82B5-B4FA0CC38581Q33883883-7B4C9EB8-FA2E-4C94-B05C-6C5D7AE24788Q33895058-D2B1AB30-0108-4602-8ABE-E75B73F61293Q33910496-9598D789-BEA7-414B-AE7C-D5DD907CD2E5Q33938498-2C165A9C-5469-4F66-974F-D027E5816C7BQ33942651-C732867B-B794-4BC5-ADCB-E0ED66C8EAA9Q33995386-EDA44E24-A42A-4FEC-A8AF-2C95377758EAQ34056876-0FBCB870-FE79-4F51-8B88-FEADFE02064FQ34064191-7A4F22A5-FB51-47E5-AC40-B0D486D65C97Q34083986-069848EF-79FC-4535-962F-4D0AA7816A29Q34144814-AE26F818-9BC7-4541-AE6F-B016376793FEQ34167746-18F99D5E-56D2-4A2C-B844-622DDE66D87EQ34188358-476D933A-E957-41E4-A7EF-E9C5686578DCQ34190813-3597EF4A-55F3-46DE-9090-2031C83DD4E8Q34208267-36EC882A-A998-44ED-B7CB-62B94FD10FC7Q34212341-C85548C7-BEC6-408A-B1F5-DB6E3C04E86F
P50
description
Head of Medicine at the Hampstead Campus and the Royal Free Hospital
@en
immunoloog
@nl
name
Mark Pepys
@ast
Mark Pepys
@de
Mark Pepys
@en
Mark Pepys
@en-ca
Mark Pepys
@en-gb
Mark Pepys
@es
Mark Pepys
@fr
Mark Pepys
@nl
Mark Pepys
@sl
type
label
Mark Pepys
@ast
Mark Pepys
@de
Mark Pepys
@en
Mark Pepys
@en-ca
Mark Pepys
@en-gb
Mark Pepys
@es
Mark Pepys
@fr
Mark Pepys
@nl
Mark Pepys
@sl
altLabel
Mark Brian Pepys
@en
Professor Sir Mark Pepys FRS
@en
Sir Mark Brian Pepys
@en
prefLabel
Mark Pepys
@ast
Mark Pepys
@de
Mark Pepys
@en
Mark Pepys
@en-ca
Mark Pepys
@en-gb
Mark Pepys
@es
Mark Pepys
@fr
Mark Pepys
@nl
Mark Pepys
@sl
P166
P214
P244
P268
P106
P1153
56848974700
P19
P2070
mark-pepys-12078
P21
P213
0000 0000 3040 2108
P214
P244
P268
P31
P463
P496
0000-0003-2614-3248
P569
1944-09-18T00:00:00Z